


Chiral Ligand Design: A Bidentate Ligand Incorporating an Acyclic Phosphaalkene**

Julien Dugal-Tessier, Gregory R. Dake,* and Derek P. Gates*

Since Becker's landmark discovery of the first isolable phosphaalkene just over three decades ago,^[1] there has been a growing interest in low coordinate multiply bonded phosphorus compounds.^[2] In fact, these species, although once considered exotic, are now being utilized in catalysis and materials science. As a consequence of their excellent π -acceptor properties, there has been considerable recent interest in the development of low valent phosphorus ligands for catalysis.^[3] Of particular significance are those in which the P=C donor moiety is incorporated into a cyclic structure (i.e. phosphinines,^[4] phosphaferrrocenes,^[5] and phospholides^[6]). Ligands containing acyclic P=C bonds are less well-developed, however the diphosphinidene-cyclobutenes (dpcb) have been demonstrated to be highly effective in catalytic transformations.^[7] We,^[8] and others,^[9] have also reported examples of acyclic P(sp²),N(sp²) phosphaalkene ligands, however their application in catalysis is still at a preliminary stage of development.

The design of asymmetric ligands for transition elements has had a profound impact on the field of synthetic organic chemistry. Of particular importance in asymmetric catalysis are the sp³ hybridized phosphane ligands which are excellent sigma donors and weak π -acceptors (binap, DuPhos, etc.). Modification of the steric and electronic properties of the metal's supporting ligands provides a means to optimize the selectivity and activity of a catalyst. π -Accepting ligands are also of considerable importance in catalysis, however the classic π -accepting ligands used in inorganic chemistry (CO, bipy) cannot be trivially reconstituted into "chiral versions" for asymmetric catalysis. To our knowledge, the only enantiomerically pure P(sp²)-based ligands are based on cyclic phosphinines and phosphaferrrocenes.^[4c,5,10–12] Consequently, the introduction of low valent, π -accepting phosphorus atoms within a readily available chiral ligand framework may fill an important gap in modern ligand design.


Here we report a synthetic strategy to air- and moisture-stable chiral, enantioenriched phosphaalkene ligands. Our approach provides a convergent and highly modular means for future tailoring of the ligand's steric and electronic properties (Scheme 1). Importantly, the stereogenic center



Scheme 1. Modular strategy for the preparation of chiral oxazoline-based phosphaalkenes. R¹, R² and R³ represent adjustable substituents.

present in the ligand is derived directly from the chiral pool. The phosphaalkene substituents (R¹ and R²) can be easily adjusted through selection of precursors. The "linker" moiety must be selected to avoid undesired reactivity of phosphaalkenes such as cycloadditions or 1,3-hydrogen migrations. The effectiveness of this new phosphaalkene as a bidentate chelating P(sp²),N(sp²) ligand is demonstrated through the isolation of an iridium(I) complex.

Amino acids are cheap, readily available sources of chirality on which to build the chiral oxazoline-containing ketone precursors to phosphaalkenes. The known oxazoline **1** was prepared in two steps from L-valine using a modified literature procedure (Scheme 2).^[13,14] Our attempts to deprotonate **1** using LDA or *n*BuLi were unsuccessful. Fortunately, treatment of **1** with 1 equivalent each of *sec*-BuLi and TMEDA for one hour at –78 °C formed the desired



Scheme 2. Synthesis of phosphaalkene ligand. a) NaBH₄, I₂, THF, 60 °C, 18 h (92%); b) isobutyric acid, xylenes, 130 °C (58%); c) 1. *s*BuLi, TMEDA, THF, –78 °C; 2. ethyl benzoate, THF, –78 °C to 25 °C (49%); d) 1. MesP(SiMe₃)Li, THF, –78 °C to 25 °C; 2. Me₃SiCl quench (52%). THF = tetrahydrofuran, Bu = butyl, TMEDA = N,N,N',N'-tetramethylethylenediamine, Mes = 2,4,6-trimethylphenyl.

[*] J. Dugal-Tessier, Prof. Dr. G. R. Dake, Prof. Dr. D. P. Gates
Department of Chemistry, University of British Columbia
2036 Main Mall, Vancouver, BC, V6T 1Z1 (Canada)
Fax: (+1) 604-822-2847
E-mail: gdake@chem.ubc.ca
dgates@chem.ubc.ca

[**] We gratefully acknowledge the following funding sources: The Natural Sciences and Engineering Research Council of Canada (NSERC Discovery and Research Tools grants to G.R.D. and D.P.G. and a PGS D scholarship to J.D.-T.), The Canada Foundation for Innovation, and The BC Knowledge Development Fund. We thank Joshua I. Bates for crystallographic work.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.200802949>.

carbanion.^[15] Claisen-type condensation of this anion with ethyl benzoate formed ketone **2** in 49% isolated yield. Importantly, these synthetic steps can be performed without recourse to flash chromatography. Ketone **2** was fully characterized using NMR spectroscopy (¹H, ¹³C), mass spectrometry [HRMS (**2**-Na⁺): *m/z* 282.1469 (found); 282.1470 (calcd)], infrared spectroscopy and elemental analysis. Compound **2** showed an optical rotation [α]_D²² = −28.1 deg cm³ g^{−1} dm^{−1} (*c* = 1.3 × 10^{−3} g cm^{−3}, CHCl₃).

With ketone **2** in hand, the phospho-Peterson reaction, a general and clean route to phosphalkenes,^[16] was attempted as the P=C bond forming step. A solution of ketone **2** in THF was added dropwise to a cooled (−78 °C) solution of MesP(Li)SiMe₃ in THF. The reaction mixture was warmed slowly to room temperature (1 h) whereupon an aliquot was removed for analysis by ³¹P NMR spectroscopy. Importantly, the signal assigned to MesP(Li)SiMe₃ (δ = −187 ppm) was replaced by a new singlet resonance at 244 ppm which is consistent with that expected for a phosphalkene (cf. MesP=CPh₂: δ = 233 ppm). The presence of a single signal suggests that only one isomer is formed. The product was recrystallized from *n*-pentane to afford colorless crystals of *E*-**3a** (yield 52%) which were characterized crystallographically (Figure 1). The optical rotation of *E*-**3a** was [α]_D²² =





Figure 1. Molecular structure of *E*-**3a** (50% probability ellipsoids). All hydrogen atoms are omitted for clarity. Selected bond lengths [Å] and angles [°]: P(1)–C(1) 1.826(2), P(1)–C(10) 1.679(2), C(10)–C(17) 1.529(3), C(17)–C(20) 1.511(3), C(20)–N(1) 1.248(3), C(20)–O(1) 1.356(3); C(1)–P(1)–C(10) 105.3(1), P(1)–C(10)–C(17) 119.2(2), C(10)–C(17)–C(20) 108.9(2), C(17)–C(20)–N(1) 127.6(2), C(17)–C(20)–O(1) 113.7(2).


−65.8 deg cm³ g^{−1} dm^{−1} (*c* = 5.0 × 10^{−3} g cm^{−3}, CHCl₃). Perhaps most remarkable is the air- and moisture-stability of compound *E*-**3a**. The ³¹P NMR spectrum of a THF solution of the phosphalkene exposed to oxygen and/or water shows no change. Moreover, crystals of *E*-**3a** have been stored on the open benchtop for months without any degradation. This stability, a relatively unusual property for phosphalkenes, allows for the manipulation of this compound without the need for special precautions.

To illustrate the modularity of our synthetic route to chiral phosphalkenes, we have prepared two additional phosphalkenes, **3b** (yield 50%) and **3c** (yield 93%). These compounds are conveniently prepared following the same route as described for **3a**. The C-substituent is modified by employing



a *p*-methoxyphenyl moiety (**3b**) in place of the phenyl group (**3a**). In addition, the steric bulk of the P-substituent is increased in **3c** by employing the 2,4,6-tri(isopropyl)phenyl moiety. Each new phosphalkene was characterized by ³¹P NMR spectroscopy (**3b**: δ = 245 ppm; **3c**: δ = 248 ppm), ¹H NMR spectroscopy and mass spectrometry (**3b**: [*M*⁺] 423; **3c**: [*M*⁺] 477).

The complexation of *E*-**3a** to late transition metals for catalysis applications is of particular interest. Iridium complexes have been used to catalyze asymmetric hydrogenation, allylic alkylation and hydroformylation, amongst other transformations.^[17] A mixture of *E*-**3a** and [(cod)IrCl]₂ in the presence of AgOTf as a halide acceptor was dissolved in CH₂Cl₂ and was stirred for 30 min whereupon the solution was separated from a white precipitate of AgCl (Scheme 3).



Scheme 3. Synthesis of iridium complex **4**. a) [(cod)IrCl]₂, AgOTf, CH₂Cl₂, RT, 30 min (72%). cod = 1,5-cyclooctadiene, OTf = trifluoromethanesulfonate.

Subsequently, the reaction mixture was analyzed by ³¹P NMR spectroscopy that showed a new singlet resonance at 197 ppm which is shifted upfield considerably from *E*-**3a** ($\Delta\delta$ = −47 ppm) and is consistent with that expected for iridium(I) complex **4**. For comparison, similar upfield shifts are observed for iridium(III) complexes of related phosphalkenes [$\Delta\delta$ = −50 ppm, L = dpcb; $\Delta\delta$ = −41 ppm, L = Mes^{*}P=C(py)H].^[18,19] Complex **4** was further characterized by ¹H and ¹³C NMR spectroscopy and elemental analysis which all provided support for the retention of the cod ligand.

The chiral phosphalkene (*E*-**3a**) and its iridium(I) complex (**4**) were each characterized crystallographically (Figures 1 and 2).^[20] Importantly, the structural data were consistent with the enantiomeric purity of these new phosphalkene species and the retention of the (*S*)-configuration from L-valine.^[21] The P=C bond length of complex **4** [1.663(5) Å] is similar in length to the free ligand *E*-**3a** [1.679(2) Å] and is typical of the bond lengths found for P=C bonds. This observation is similar to that observed between structures of π -accepting ligand dpcb and its metal complexes and cannot solely be used to judge the π -acceptor properties of the ligand.^[22] Interestingly, the angle at phosphorus expands significantly upon complexation and approaches




Figure 2. Molecular structure of **4** (50% probability ellipsoid). All hydrogen atoms are omitted for clarity. Selected bond lengths [Å] and angles [°]: P(4)–C(1) 1.806(5), P(4)–C(10) 1.663(5), C(10)–C(17) 1.546(6), C(17)–C(20) 1.514(7), C(20)–N(1) 1.290(6), C(20)–O(1) 1.335(5), P(4)–Ir(1) 2.212(1), N(1)–Ir(1) 2.077(4); C(1)–P(4)–C(10) 114.3(2), P(4)–C(10)–C(17) 118.5(4), C(10)–C(17)–C(20) 111.3(4), C(17)–C(20)–N(1) 129.4(4), C(17)–C(20)–O(1) 114.7(4), C(20)–N(1)–Ir(1) 129.1(3), N(1)–Ir(1)–P(4) 85.6(1), Ir(1)–P(4)–C(10) 121.0(2).

ideal sp^2 hybridization [C–P–C = 105.3(1)° in **E-3a**, 114.3(2)° in **4**]. The P–Ir bond in **4** [2.212(1) Å] is shorter than that found in a phosphinine–iridium(I) complex [ca. 2.4 Å],^[23] a phosphapherocene–iridium(I) complex [avg. 2.298(2) Å],^[24] and a dpcb–iridium(III) complex [avg. 2.525(21) Å].^[19] To our knowledge, these are the only other structurally characterized iridium complexes containing sp^2 phosphorus. For comparison, an analogous iridium(I)–cod complex containing the Pfaltz ligand, $Ph_2P-C_6H_4(2-ox)$, exhibits a P–Ir bond length of 2.266(3) Å which is longer than that found in **4**.^[25] The Ir–N distance in **4** [2.077(4) Å] is also similar to that found in the Pfaltz complex [2.119(7) Å].

In closing, we report the synthesis of the first examples of a new class of enantiomerically pure phosphalkenes and, by forming an iridium(I) complex, demonstrate their effectiveness as a bidentate chelating ligand. This air-stable phosphalkene is of considerable interest as a π -accepting ligand in asymmetric catalysis, a topic which is currently under active investigation.

Received: June 20, 2008

Revised: August 8, 2008

Published online: September 15, 2008

Keywords: iridium · ligand design · N,P-ligands · phosphalkenes · phosphorus

[1] G. Becker, *Z. Anorg. Allg. Chem.* **1976**, 423, 242.

[2] See, for example: a) K. B. Dillon, F. Mathey, J. F. Nixon, *Phosphorus: The Carbon Copy*, Wiley, Chichester, **1998**; b) F. Mathey, *Angew. Chem.* **2003**, 115, 1616; *Angew. Chem. Int. Ed.* **2003**, 42, 1578; c) L. Weber, *Eur. J. Inorg. Chem.* **2000**, 2425; d) R. Appel in *Multiple Bonds and Low Coordination in*

Phosphorus Chemistry (Eds.: M. Regitz, O. J. Scherer), Thieme, Stuttgart, **1990**.

[3] For recent reviews highlighting the use of low-coordinate phosphorus compounds in catalysis see: a) P. Le Floch, *Coord. Chem. Rev.* **2006**, 250, 627; b) L. Weber, *Angew. Chem.* **2002**, 114, 583; *Angew. Chem. Int. Ed.* **2002**, 41, 563.

[4] For a recent review, see: C. Müller, D. Vogt, *Dalton Trans.* **2007**, 5505; for recent work on mono- and diphosphine complexes, see: a) C. Müller, Z. Freixa, M. Lutz, A. L. Spek, D. Vogt, P. W. N. M. van Leeuwen, *Organometallics* **2008**, 27, 834; b) H. Lesnard, T. Cantat, P. Le Floch, I. Demachy, Y. Jean, *Chem. Eur. J.* **2007**, 13, 2953; c) O. Piechaczyk, T. Cantat, N. Mezaillies, P. Le Floch, *J. Org. Chem.* **2007**, 72, 4228; d) C. Elschenbroich, J. Six, K. Harms, *Chem. Commun.* **2006**, 3429; e) C. Müller, L. G. Lopez, H. Kooijman, A. L. Spek, D. Vogt, *Tetrahedron Lett.* **2006**, 47, 2017; f) M. Doux, L. Ricard, P. Le Floch, Y. Jean, *Organometallics* **2006**, 25, 1101; g) P. Rosa, N. Mezaillies, L. Ricard, F. Mathey, P. Le Floch, Y. Jean, *Angew. Chem.* **2001**, 113, 1291; *Angew. Chem. Int. Ed.* **2001**, 40, 1251; h) B. Breit, R. Winde, T. Mackewitz, R. Paciello, K. Harms, *Chem. Eur. J.* **2001**, 7, 3106; i) P. Rosa, N. Mezaillies, L. Ricard, F. Mathey, P. Le Floch, *Angew. Chem.* **2000**, 112, 1893; *Angew. Chem. Int. Ed.* **2000**, 39, 1823.

[5] See, for example: a) M. Ogasawara, A. Ito, K. Yoshida, T. Hayashi, *Organometallics* **2006**, 25, 2715; b) A. Suarez, C. W. Downey, G. C. Fu, *J. Am. Chem. Soc.* **2005**, 127, 11244; c) R. Shintani, G. C. Fu, *Angew. Chem.* **2003**, 115, 4216; *Angew. Chem. Int. Ed.* **2003**, 42, 4082; d) R. Shintani, G. C. Fu, *J. Am. Chem. Soc.* **2003**, 125, 10778; e) R. Shintani, G. C. Fu, *Org. Lett.* **2002**, 4, 3699; f) S. O. Agostsson, C. H. Hu, U. Englert, T. Marx, L. Wesemann, C. Ganter, *Organometallics* **2002**, 21, 2993; g) K. Tanaka, G. C. Fu, *J. Org. Chem.* **2001**, 66, 8177; h) M. Ogasawara, K. Yoshida, T. Hayashi, *Organometallics* **2001**, 20, 3913; i) K. Tanaka, S. Qiao, M. Tobisu, M. M. C. Lo, G. C. Fu, *J. Am. Chem. Soc.* **2000**, 122, 9870; j) X. Sava, L. Ricard, F. Mathey, P. Le Floch, *Organometallics* **2000**, 19, 4899; k) C. Ganter, C. Kaulen, U. Englert, *Organometallics* **1999**, 18, 5444.

[6] J. Grundy, B. Donnadieu, F. Mathey, *J. Am. Chem. Soc.* **2006**, 128, 7716.

[7] See, for example: a) A. Hayashi, T. Yoshitomi, K. Umeda, M. Okazaki, F. Ozawa, *Organometallics* **2008**, 27, 2321; b) F. Ozawa, M. Yoshifuji, *Dalton Trans.* **2006**, 4987; c) H. Katayama, M. Nagao, T. Nishimura, Y. Matsui, K. Umeda, K. Akamatsu, T. Tsuruoka, H. Nawafune, F. Ozawa, *J. Am. Chem. Soc.* **2005**, 127, 4350; d) H. Z. Liang, S. Ito, M. Yoshifuji, *Org. Lett.* **2004**, 6, 425; e) A. S. Gajare, K. Toyota, M. Yoshifuji, F. Ozawa, *Chem. Commun.* **2004**, 1994; f) F. Ozawa, H. Okamoto, S. Kawagishi, S. Yamamoto, T. Minami, M. Yoshifuji, *J. Am. Chem. Soc.* **2002**, 124, 10968; g) T. Minami, H. Okamoto, S. Ikeda, R. Tanaka, F. Ozawa, M. Yoshifuji, *Angew. Chem.* **2001**, 113, 4633; *Angew. Chem. Int. Ed.* **2001**, 40, 4501; h) S. Ikeda, F. Ohhata, M. Miyoshi, R. Tanaka, T. Minami, F. Ozawa, M. Yoshifuji, *Angew. Chem.* **2000**, 112, 4686; *Angew. Chem. Int. Ed.* **2000**, 39, 4512.

[8] J. Dugal-Tessier, G. R. Dake, D. P. Gates, *Organometallics* **2007**, 26, 6481.

[9] For recent work, see: a) A. Hayashi, M. Okazaki, F. Ozawa, R. Tanaka, *Organometallics* **2007**, 26, 5246; b) F. Basuli, J. Tomaszewski, J. C. Huffman, D. J. Mindiola, *J. Am. Chem. Soc.* **2003**, 125, 10170; c) A. Ionkin, W. Marshall, *Chem. Commun.* **2003**, 710; d) A. Dargulis, M. Brookhart, P. S. White, *Organometallics* **2002**, 21, 5935; e) A. S. Ionkin, W. J. Marshall, *Heteroat. Chem.* **2002**, 13, 662.

[10] B. Breit, *J. Mol. Catal. A* **1999**, 143, 143.

[11] B. Breit, *Chem. Commun.* **1996**, 2071.

[12] Mathey and co-workers have previously reported an acyclic L-menthyl-containing phosphalkene as a [W(CO)₅] complex at phosphorus (i.e. [(L-menthyl){(CO)₅W}P=CH(*i*Pr)]). The free

- phosphaalkene was not reported. See, R. De Vaumas, A. Marinetti, L. Ricard, F. Mathey, *J. Am. Chem. Soc.* **1992**, *114*, 261.
- [13] M. J. McKennon, A. I. Meyers, K. Drauz, M. Schwarm, *J. Org. Chem.* **1993**, *58*, 3568.
- [14] M. J. Kurth, O. H. W. Decker, H. Hope, M. D. Yanuck, *J. Am. Chem. Soc.* **1985**, *107*, 443.
- [15] R. Luisi, V. Capriati, S. Florio, T. Vista, *J. Org. Chem.* **2003**, *68*, 9861.
- [16] M. Yam, J. H. Chong, C. W. Tsang, B. O. Patrick, A. E. Lam, D. P. Gates, *Inorg. Chem.* **2006**, *45*, 5225.
- [17] See, for example: a) M. G. Schrems, E. Neumann, A. Pfaltz, *Angew. Chem.* **2007**, *119*, 8422; *Angew. Chem. Int. Ed.* **2007**, *46*, 8274; b) M. Engman, J. S. Diesen, A. Paptchikhine, P. G. Andersson, *J. Am. Chem. Soc.* **2007**, *129*, 4536; c) M. Schelwies, P. Dübon, G. Helmchen, *Angew. Chem.* **2006**, *118*, 2526; *Angew. Chem. Int. Ed.* **2006**, *45*, 2466; d) D. J. Fox, S. B. Duckett, C. Flaschenriem, W. W. Brennessel, J. Schneider, A. Gunay, R. Eisenberg, *Inorg. Chem.* **2006**, *45*, 7197; e) A. Alexakis, D. Polet, *Org. Lett.* **2004**, *6*, 3529.
- [18] M. van der Sluis, V. Beverwijk, A. Termaten, E. Gavrilova, F. Bickelhaupt, H. Kooijman, N. Veldman, A. L. Spek, *Organometallics* **1997**, *16*, 1144.
- [19] A. Hayashi, T. Ishiyama, M. Okazaki, F. Ozawa, *Organometallics* **2007**, *26*, 3708.
- [20] CCDC 692226 (*E*-**3a**) and 692227 (**4**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- [21] Analysis of the Flack parameters for each structure [0.13(9) for *E*-**3**; 0.003(5) for **4**] suggested that the data was refined on the correct enantiomer and that the compounds were close to enantiomeric purity.
- [22] The P=C bond lengths in dpcb complexes are also similar to those of the free ligand. See, for example: F. Ozawa, S. Kawagishi, T. Ishiyama, M. Yoshifuji, *Organometallics* **2004**, *23*, 1325. In addition, the ^{13}C NMR spectroscopic data for the P=C moiety [**3a**: $\delta = 203.3$ ppm ($^1J_{\text{PC}} = 48$ Hz); **4**: $\delta = 175.5$ ppm ($^1J_{\text{PC}} = 58$ Hz)] are consistent with that expected for a π -accepting ligand and are also observed in the case of the π -accepting dpcb. We speculate that the apparent contradiction in the expected P=C bond length upon coordination may be a consequence of increased phosphorus s-orbital character in the P=C σ -bond as evinced by the C-P-C angles.
- [23] B. Schmid, L. M. Venzani, T. Gerfin, V. Gramlich, F. Mathey, *Inorg. Chem.* **1992**, *31*, 5117.
- [24] X. Sava, N. Mezailles, L. Ricard, F. Mathey, P. Le Floch, *Organometallics* **1999**, *18*, 807.
- [25] a) S. P. Smidt, F. Menges, A. Pfaltz, *Org. Lett.* **2004**, *6*, 2023; b) P. Schnider, G. Koch, R. Prétôt, G. Z. Wang, F. M. Bohnen, C. Krüger, A. Pfaltz, *Chem. Eur. J.* **1997**, *3*, 887.